S E L PHARMACIE CAMILLE SEE : revenue, balance sheet and financial ratios

S E L PHARMACIE CAMILLE SEE is a French company founded 18 years ago, specialized in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé. Based in COLMAR (68000), this company of category PME shows in 2022 a revenue of 1.9 M€. Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.

Data updated on 2026-04-25

Sources : INPI & INSEE SIRENE - Processing : Ministry of Economy

Financial history - S E L PHARMACIE CAMILLE SEE (SIREN 502801616)
Indicator 2025 2024 2023 2022 2021 2020 2019 2016 2015
Revenue N/C N/C N/C 1 869 347 € N/C 1 601 267 € 1 567 799 € N/C 1 214 208 €
Net income 115 849 € 115 076 € 102 813 € 160 067 € 120 958 € 111 637 € 116 243 € 95 399 € 63 131 €
EBITDA N/C N/C N/C 223 680 € N/C 153 867 € 163 196 € N/C 112 557 €
Net margin N/C N/C N/C 8.6% N/C 7.0% 7.4% N/C 5.2%

Revenue and income statement

In 2025, S E L PHARMACIE CAMILLE SEE generates positive net income of 116 k€. Net income represents the final profit after all expenses (operating, financial, exceptional) and corporate tax. Change over 2015-2025: 63 k€ -> 116 k€.

Net income (2025) ?
Net income
Definition
Profit or loss after all expenses, including taxes and exceptional items.
Formula
Current income + Exceptional income - Income tax

115 849 €

Loading income statement...

Chart evolution

Show :

Assets

Loading data...

Liabilities

Loading data...

Solvency and debt ratios

The debt ratio (= Financial debt / Equity x 100) stands at 32%. Debt remains under control: the company retains capacity to raise new debt if needed. Financial autonomy (= Equity / Total assets x 100) reaches 56%. This high autonomy means the company finances most of its assets through equity, a sign of strength.

Debt ratio (2025) ?
Debt ratio
Definition
Measures the proportion of debt to equity.
Formula
(Financial debt / Equity) x 100
Interpretation
< 50% : Low
50-100% : Moderate
> 100% : High

32.122%

Financial autonomy (2025) ?
Financial autonomy
Definition
Share of equity in the company's total financing.
Formula
(Equity / Total assets) x 100
Interpretation
> 30% : Good autonomy
20-30% : Average
< 20% : Low

56.278%

Asset age ratio (2025) ?
Asset age ratio
Definition
Measures the degree of wear of tangible assets.
Formula
Accumulated depreciation / Gross fixed assets x 100
Interpretation
< 50% : Recent assets
50-70% : Normal wear
> 70% : Aging assets

13.8%

Solvency indicators evolution
S E L PHARMACIE CAMILLE SEE

Sector positioning

Debt ratio
32.12 2025
2023
2024
2025
Q1: 13.71
Med: 49.76
Q3: 129.07
Good

In 2025, the debt ratio of S E L PHARMACIE CAMILLE SEE (32.12) ranks below the median of the sector. This ratio measures the weight of debt relative to equity. This controlled position reflects prudent management.

Financial autonomy
56.28% 2025
2023
2024
2025
Q1: 33.42%
Med: 53.71%
Q3: 72.08%
Good

In 2025, the financial autonomy of S E L PHARMACIE CAMILLE SEE (56.3%) ranks above the median of the sector. This ratio represents the share of equity in total financing. This comfortable position offers an appreciable safety margin.

Liquidity ratios

The liquidity ratio (= Current assets / Current liabilities) stands at 101.72. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months.

Liquidity ratio (2025) ?
Liquidity ratio
Definition
Ability to meet short-term debts with current assets.
Formula
Current assets / Current liabilities
Interpretation
> 1.5 : Very good
1-1.5 : Fair
< 1 : Liquidity risk

101.725

Liquidity indicators evolution
S E L PHARMACIE CAMILLE SEE

Sector positioning

Liquidity ratio
101.72 2025
2023
2024
2025
Q1: 131.03
Med: 182.29
Q3: 258.7
Watch

In 2025, the liquidity ratio of S E L PHARMACIE CAMILLE SEE (101.72) ranks in the bottom 25% of the sector. This ratio measures the ability to cover short-term debt with current assets. A ratio below 1 may signal potential cash flow tensions.

Working capital requirement (WCR) and payment terms

Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments. Average customer payment term: 396 days (formula: Customer receivables / Revenue incl. VAT x 360). Supplier term: 1633 days. Excellent situation: suppliers finance 1237 days of the operating cycle (retail model).

Operating WCR (2025) ?
Operating WCR
Definition
Financing requirement generated by the operating cycle (inventory + receivables - trade payables).
Formula
Inventory + Customer receivables - Trade payables
Interpretation
Negative = cash released
Positive = financing needed

0 €

Customer credit (2025) ?
Customer credit (days)
Definition
Average payment term granted to customers.
Formula
(Customer receivables / Revenue incl. VAT) x 360
Interpretation
< 45j : Good
45-60j : Average
> 60j : Long

396 j

Supplier credit (2025) ?
Supplier credit (days)
Definition
Average payment term obtained from suppliers.
Formula
(Trade payables / Purchases incl. VAT) x 360
Interpretation
The longer the term, the better for cash flow

1633 j

Inventory turnover (2025) ?
Inventory turnover (days)
Definition
Average storage duration for goods or materials.
Formula
(Inventory / Cost of goods) x 360
Interpretation
The lower the ratio, the faster the turnover

0 j

WCR and payment terms evolution
S E L PHARMACIE CAMILLE SEE

Positioning of S E L PHARMACIE CAMILLE SEE in its sector

Comparison with sector Commerce de détail de produits pharmaceutiques en magasin spécialisé

Valuation estimate

Based on 277 transactions of similar company sales in 2025, the value of S E L PHARMACIE CAMILLE SEE is estimated at 1 840 275 € (range 1 248 819€ - 2 887 645€). This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.

Estimated enterprise value 2025
277 transactions
1248k€ 1840k€ 2887k€
1 840 275 € Range: 1 248 819€ - 2 887 645€
NAF 5 année 2025

Valuation method used

Net Income Multiple
115 849 € × 15.9x = 1 840 275 €
Range: 1 248 819€ - 2 887 645€

Only this financial indicator is available for this company.

Valuation evolution

How is this estimate calculated?

This estimate is based on the analysis of 277 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.

  • EBITDA Multiple: Preferred method for profitable SMEs. EBITDA reflects the ability to generate cash.
  • Revenue Multiple: Used for growing companies or those with low profitability. Reflects commercial potential.
  • Net Income Multiple: Relevant for mature companies with stable results.

This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).

Similar companies (Commerce de détail de produits pharmaceutiques en magasin spécialisé)

Compare S E L PHARMACIE CAMILLE SEE with other companies in the same sector:

Voir toutes les statistiques du secteur Commerce de détail de produits pharmaceutiques en magasin spécialisé

Frequently asked questions about S E L PHARMACIE CAMILLE SEE

What is the revenue of S E L PHARMACIE CAMILLE SEE ?

The revenue of S E L PHARMACIE CAMILLE SEE in 2022 is 1.9 M€.

Is S E L PHARMACIE CAMILLE SEE profitable?

Yes, S E L PHARMACIE CAMILLE SEE generated a net profit of 116 k€ in 2025.

Where is the headquarters of S E L PHARMACIE CAMILLE SEE ?

The headquarters of S E L PHARMACIE CAMILLE SEE is located in COLMAR (68000), in the department Haut-Rhin.

Where to find the tax return of S E L PHARMACIE CAMILLE SEE ?

The tax return of S E L PHARMACIE CAMILLE SEE is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).

In which sector does S E L PHARMACIE CAMILLE SEE operate?

S E L PHARMACIE CAMILLE SEE operates in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé (NAF code 47.73Z). See the 'Sector positioning' section above to compare the company with its competitors.